The first new type of medication in decades to help fight against schizophrenia was approved on Thursday by the U.S.
Shares in Bristol-Myers Squibb (BMY) surged Friday, after the Food and Drug Administration approved the drugmaker's novel ...
The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the ...
Bristol-Myers Squibb shares rose in premarket trade on Friday after the Food and Drug Administration approved a schizophrenia ...
The U.S. Food and Drug Administration has approved a new drug for adults with schizophrenia,  the FDA announced Thursday.
Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than ...
The U.S. Food and Drug Administration has granted approval to Cobenfy, the first new schizophrenia drug in decades.
The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in ...
Cobenfy was approved to reduce the psychotic symptoms associated with schizophrenia. It is a new type of medicine that works ...
Bristol Myers obtained the drug Cobenfy, also known as KarXT, through its $14 billion takeover of Karuna Therapeutics last ...
Cobenfy gives patients an alternative to drugs with troublesome side effects.